Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Reversine
Cat. No.:
OB0225LY-0340
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Product Overview
Description:
Reversine is a potent inhibitor of Aurora A/B/C.
Synonym:
656820-32-5; 2-(4-Morpholinoanilino)-6-cyclohexylaminopurine; N6-cyclohexyl-N2-(4-morpholinophenyl)-7H-purine-2,6-diamine; N6-Ccyclohexyl-N2-(4-morpholinophenyl)-9H-purine-2,6-diamine; N6-Cyclohexyl-N2-[4-(4-morpholinyl)phenyl]-1H-purine-2,6-diamine
CAS No.:
656820-32-5
Compound CID:
210332
Formula:
C21H27N7O
Formula Weight:
393.49
Specification
Relative Density:
1.343 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Reversine can be used in stem cell research, especially play an important role in the field of induced stem cell differentiation and regenerative medicine.
Library Information
Targets:
Aurora kinase
Receptors:
A3; Aurora A; Aurora B; Aurora C
Pathways:
Chromatin/Epigenetic; Neuronal signaling; Autophagy; Cell cycle/Checkpoint; GPCR/G protein
Plate Number:
AOCL-5
Plate Location:
d4
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
5 mg/mL; 12.71 mM
Ethanol Max Solubility:
<1 mg/mL (insoluble or slightly soluble)
